Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues.

By M. Thun, S. J. Henley, C. Patrono. Journal of the National Cancer Institute, 2002

1,438 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Roles of the immune system in cancer: from tumor initiation to metastatic progression (2018, neutral): “Interestingly,long-termuseofnonsteroidal anti-inflammatorydrugs(NSAIDs),whichsuppressesthe immunesystem,hasbeenlinkedtoalowerriskofcancer (Thun et al. 2002).”
Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic (2004, neutral): “produce anti-inflammatory inhibition of COX-2 (67).”
Tumor microenvironment: The role of the tumor stroma in cancer (2007, result): “Prevention of other types of cancer has been inferred but not yet confirmed by large trials [Schreinemachers and Everson, 1994; Castelao et al., 2000; Thun et al., 2002], adding support to targeting inflammation for cancer prevention.”
Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition (2004, background): “…were further supported by epidemiological studies of humans who use aspirin and other NSAIDs chronically; it was found in various studies that incidence of various cancers, including, colon, intestinal, gastric, breast, and bladder cancers, were reduced up to 40 to 50% (Thun et al., 2002).”
Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms. (2004, background): “Numerous epidemiologic studies found that long-term use of COX-2 inhibitors (nonsteroidal antiinflammatory drugs) is associated with a lower risk of colorectal cancer, adenomatous polyps, and perhaps other types of cancer (121).”